BGI Genomics, today announced that two multiplex tests for SARS-CoV-2 and Influenza A/B produced by its subsidiary BGI PathoGenesis Pharmaceutical Technology Co., Ltd, have received CE mark.
Real-time Fluorescent RT-PCR kit for detecting SARS-CoV-2(ORF1ab), Influenza A Virus and Influenza B Virus, together with Multiplex Real-time Fluorescent RT-PCR kit for detecting SARS-CoV-2(ORF1ab and N), Influenza A Virus and Influenza B are multiplex reverse transcription polymerase chain reaction assay intended for the simultaneous qualitative detection and differentiation of SARS-CoV-2, Influenza A virus, and Influenza B virus in throat swabs samples.
The clinical symptoms of influenza A virus, influenza B virus are similar to COVID-19. Rapid detection and precise differential identification of causative pathogen play an important role in pandemic control and prevention. The new multiplex tests which detect three viruses in a single reaction at one time, can help the rapid triage of testing populations.
These new tests are a key additional step in BGI’s fighting against the COVID-19 pandemic, which has already included: Providing COVID-19 Local Laboratory Solutions; Supplying Real-Time Fluorescent RT-PCR kit for 2019-nCoV and Antibody Detection Kit (ELISA) for COVID-19. The newly released tests also provide a sensitive nucleic-acid-based solution for evaluating the infection situation of SARS-CoV-2 and Influenza A/B in specimens from patients during the upcoming season of influenza in mist of COVID-19 pandemic.
